Pfizer Inc. (PFE)

35.05
0.18 0.50
NYSE : Health Technology
Prev Close 34.87
Open 34.96
Day Low/High 34.80 / 35.11
52 Wk Low/High 33.97 / 46.47
Volume 8.60M
Avg Volume 24.93M
Exchange NYSE
Shares Outstanding 5.53B
Market Cap 191.43B
EPS 1.90
P/E Ratio 15.59
Div & Yield 1.44 (3.98%)
Pfizer Lifts 2019 Earnings Forecast as Biopharma Sales Drive Q1 Profit Beat

Pfizer Lifts 2019 Earnings Forecast as Biopharma Sales Drive Q1 Profit Beat

Pfizer posted stronger-than-expected first quarter earnings Tuesday, and boosted the mid-point of its full-year profit forecast thanks to anticipated gains in consumer healthcare.

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

Hey, Apple, Here's What This Shareholder Wants to Hear From You: Market Recon

We also dissect the S&P 500's record run, check out China's latest economic data and take a skeptical glance at an idea floated by a couple Fed officials.

Stocks Drift As Google Sales Miss, China Factory Slip, Clips Record S&P 500 High

Stocks Drift As Google Sales Miss, China Factory Slip, Clips Record S&P 500 High

Global stocks slipped lower for a second consecutive session Tuesday, pulling U.S. equity futures into the red, as investors reacted to renewed weakness in China's manufacturing sector and braced for the impact of softer-than-expected revenue gains from online ad giant Alphabet Inc.

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS

PFIZER REPORTS FIRST-QUARTER 2019 RESULTS

Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2019 and raised the midpoint of its 2019 financial guidance for adjusted diluted EPS (2).

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

Google, Apple, AMD, General Electric and General Motors - 5 Things You Must Know

U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.

Dow Futures Gain as Solid Growth, Tame Inflation, Surprising Profits Drive Bulls

Dow Futures Gain as Solid Growth, Tame Inflation, Surprising Profits Drive Bulls

Global stocks were mixed Monday as investors extended bets that surging economic growth, stronger-than-expected corporate earnings and a potentially dovish Federal Reserve will continue to push U.S. stocks to fresh record highs.

Pfizer Receives Positive CHMP Opinion For TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

Pfizer Receives Positive CHMP Opinion For TALZENNA® (talazoparib) For Patients With Inherited (Germline) BRCA-Mutated Locally Advanced Or Metastatic Breast Cancer

Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending TALZENNA ® (talazoparib), an oral poly (ADP-ribose) polymerase (PARP)...

Pfizer Becomes #4 Most Shorted Dow Stock, Replacing Merck

Pfizer Becomes #4 Most Shorted Dow Stock, Replacing Merck

The most recent short interest data has been released for the 04/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

News Surrounds 3 Small Biotechs, With a Merger Claiming One

News Surrounds 3 Small Biotechs, With a Merger Claiming One

Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.

Pfizer Hosts Annual Meeting Of Shareholders

Pfizer Hosts Annual Meeting Of Shareholders

The board of directors of Pfizer Inc. today declared a 36-cent second-quarter 2019 dividend on the company's common stock, payable June 7, 2019 to shareholders of record at the close of business on May 10, 2019.

Pfizer And Lilly Announce Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis

Pfizer And Lilly Announce Top-Line Results From Long-Term Phase 3 Study Of Tanezumab In Patients With Osteoarthritis

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.

Be Careful With Healthcare Stocks Here

Be Careful With Healthcare Stocks Here

Especially when healthcare CEOs discus political issues with analysts and reporters.

Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders

Pfizer Invites Public To Listen To Webcast Of April 25 Annual Meeting Of Shareholders

Pfizer Inc. invites investors and the general public to listen to an audio webcast of the Annual Meeting of Shareholders at 9:00 a.

10 Speculative Stock Plays in the Biotech Sector

10 Speculative Stock Plays in the Biotech Sector

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

Pfizer Announces Presentation Of Data From A Phase 2 Study Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Announces Presentation Of Data From A Phase 2 Study Of Its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated For The Prevention Of Invasive Disease And Pneumonia In Adults Aged 18 Years And Older

Pfizer Inc. (NYSE: PFE) announced today the presentation of data from a Phase 2 study of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, PF-06482077, being investigated for the prevention of invasive disease and pneumonia caused by...

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Johnson & Johnson or Pfizer: Which Big Pharma Dividend Stock Is a Better Buy?

Healthcare giants Johnson & Johnson and Pfizer offer a tough choice for dividend investors seeking the best returns.

U.S. FDA Approves IBRANCE® (palbociclib) For The Treatment Of Men With HR , HER2- Metastatic Breast Cancer

U.S. FDA Approves IBRANCE® (palbociclib) For The Treatment Of Men With HR , HER2- Metastatic Breast Cancer

Pfizer (NYSE:PFE) today announced that the U.S.

AM Best Affirms Credit Ratings Of Blue Whale Re Ltd.

AM Best Affirms Credit Ratings Of Blue Whale Re Ltd.

AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" of Blue Whale Re Ltd.

VIZIMPRO® (dacomitinib) Receives Marketing Authorization In European Union (EU) For The First-Line Treatment Of Adult Patients With EGFR-Mutated Non-Small Cell Lung Cancer

VIZIMPRO® (dacomitinib) Receives Marketing Authorization In European Union (EU) For The First-Line Treatment Of Adult Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced that the European Commission has approved VIZIMPRO ® (dacomitinib), a tyrosine kinase inhibitor (TKI), as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell...

Citigroup Is Only One of 46 Companies to Get an 'A' in Equal Pay Day Survey

Citigroup Is Only One of 46 Companies to Get an 'A' in Equal Pay Day Survey

Half of the world's largest corporations receive a failing grade in the Arjuna Capital/Proxy Impact report.

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

The stock surges on 'encouraging' results from a genome-therapy trial for the treatment of a severe type of hemophilia.

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

- Eight patients treated with SB-525 gene therapy showed dose-dependent increases in FVIII activity, with the two patients treated with the 3e13 vg/kg dose reaching normal FVIII levels

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo And Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc.

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record At $223 Billion; 2018 Sets Record $806 Billion

- Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, March 19, 2019 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc.

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

Pfizer Acquires Gene Therapy Portfolio in Deal that Could Total $636 Million

Pfizer pays $51 million up front for a 15% stake in French biopharmaceutical company Vivet.

Pfizer Secures Exclusive Option To Acquire Gene Therapy Company Vivet Therapeutics

Pfizer Secures Exclusive Option To Acquire Gene Therapy Company Vivet Therapeutics

Vivet Therapeutics ("Vivet"), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc.

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Announce Discontinuation Of Phase III JAVELIN Ovarian PARP 100 Trial In Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany and NEW YORK, March 19, 2019 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc.

Pfizer Invites Public To View And Listen To Webcast Of April 30 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of April 30 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Using Technical Analysis: Cramer's 'Mad Money' Recap (Monday 3/18/19)

Using Technical Analysis: Cramer's 'Mad Money' Recap (Monday 3/18/19)

Jim Cramer explains the art and science of technical analysis.

TheStreet Quant Rating: B (Buy)